Critically appraise and discuss recent findings on the immunopathogenesis of psoriasis, atopic dermatitis, psoriatic arthritis, and hidradenitis supperativa.
Describe recent advances in biologic and small molecule drug development for the treatment of immune-mediated inflammatory disease, with an emphasis on psoriasis, psoriatic arthritis, and atopic dermatitis.
Develop strategies to predict, prevent, and treat potential adverse effects and complications encountered with biologic agents.
Analyze recent clinical trials on the safety and efficacy of biologic and small molecule drugs for the treatment of psoriasis, psoriatic arthritis, and atopic dermatitis.
Review data regarding the comorbidities associated with psoriasis, psoriatic arthritis, and atopic dermatitis.
Through case-based presentations and discussion, develop individualized treatment plans for patients with psoriasis or AD.
DEF Biologic & Small Molecule NP/PA CME Virtual Bootcamp June 2021
Please click “Next Page” to proceed to the Test for this activity.
Details
Learning Objectives
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.- April Armstrong has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: AbbVie, BI, Bristol-Myers Squibb, Dermira, Dermavant, Eli Lilly, EPI Health, Incyte, Janssen, LEO Pharma, Modernizing Medicine, Novartis AG, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, and UCB. Non-Promotional Speaker: AbbVie, Janssen. Grant/Research Support: Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly, and UCB.
- David Cohen, MD, MPH, FAAD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Asana, Cosmetic Ingredient Review, Dermavant, Ferndale Laboratories, FIDE, FSJ, LEO, Medimetriks, Novartis, and UCB. Stock Shareholder: Brickell Biotech (past), Dermira (past), Kadmon, Medimetriks (past) and Timber Pharmaceuticals. Board of Directors: Dermira (past), Evommune, Kadmon, and Timber.
- Kara Gooding, MMS, PA-C has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Incyte, Novartis Pharmaceuticals, Pfizer, and UCB. Speaker’s Bureau: Amgen, Almirall, LEO Pharma, and Pfizer.
- Joseph Gorelick, MSN, FNP-C has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bristol Myers Squibb, Beiersdorf, Brickell, Incyte, Journey, and Novartis. Speaker’s Bureau: AbbVie, Beiersdorf, Janssen, Lilly, LEO, Novartis, Pfizer, Prugen, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and Vyne. Stock Shareholder: 10X Genomics, AbbVie (past), Alnilam Pharmaceuticals, Bioline Rx, Fortress Biotech, G1 Therapeutics, Guardiant Health, Intuitive Surgical, LTD, Moderna, and Royalty Pharma.
- Accreditation and Medical Education Support DisclosureErin Fletcher of Evolve Medical Education LLC have no real or apparent conflicts of interest to report. Stacey Moore of Physician Resources, LLC has no real or apparent conflicts of interest to report.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
4.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!